`
`
`
`
`
`Paper No. __
`Date Filed: April 10, 2017
`
`Filed On Behalf Of:
`
`Novartis AG
`
`By:
`
`Nicholas N. Kallas
`NKallas@fchs.com
`ZortressAfinitorIPR@fchs.com
`(212) 218-2100
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`NOVARTIS AG,
`Patent Owner
`
`
`
`Inter Partes Review No. 2017-01063
`
`U.S. Patent 9,006,224
`
`
`PATENT OWNER NOVARTIS’S RESPONSE TO
`PETITIONER ARGENTUM’S MOTION FOR JOINDER
`
`
`
`
`
`
`
`
`
`Patent Owner Novartis AG (“Novartis”) does not oppose the March 10,
`
`2017 joinder motion of Argentum Pharmaceuticals LLC (“Argentum”).
`
`Nevertheless, to advance the “just, speedy, and inexpensive resolution” of joint
`
`proceedings, Novartis respectfully requests that the Board order Argentum in joint
`
`proceedings (i) to rely solely on the petition and the evidence filed by Par in
`
`IPR2016-01479; (ii) to consolidate all briefing under the page limits of 37 C.F.R. §
`
`42.24 and to share the pages that are allotted for written work product to Par in
`
`IPR2016-01479; and (iii) to share with Par the time that is or will be allotted for
`
`cross and redirect examination to Par in the IPR2016-01479.
`
`
`
`Precedent exists for those limitations. See, e.g., Bungie, Inc. v. Acceleration
`
`Bay, LLC, IPR2016-00934, Paper 11 (July 8, 2016) at 13-14 (granting Bungie’s
`
`motion for joinder, ordering that petitioners consolidate all briefing under the page
`
`limits of 37 C.F.R. § 42.24, and ordering that Bungie not file any additional pages
`
`to address points of disagreement with the Activision petitioners without first
`
`moving for and obtaining the Board’s permission); ZTE USA, Inc. v. Evolved
`
`Wireless LLC, IPR2016-01280, Paper 8 (Dec. 21, 2016) at 4 (consolidating
`
`identical IPR petitions sua sponte, and ordering that petitioners “will share all time
`
`permitted for depositions and will file all papers, except for papers that do not
`
`involve the other petitioner, as a consolidated paper, and that consolidated papers
`
`will not be given additional pages or words unless otherwise authorized by the
`
`- 1 -
`
`
`
`
`
`Board.”). Cf. Teva Pharms. USA, Inc. v. Viiv Healthcare Co., IPR2015-00550,
`
`Paper 11 (June 25, 2015) at 6 (denying joinder where joinder raised the prospect
`
`that the parties and the Board would have to manage burdensome additional pages
`
`Respectfully submitted,
`
`
`
`
`
`/Nicholas N. Kallas/
`Nicholas N. Kallas
`Registration No. 32,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`of briefing).
`
`
`
`
`
`
`
`
`
`
`
`Dated: April 10, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`- 2 -
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of the foregoing Patent Owner Novartis’s Response To
`
`Petitioner Argentum’s Motion For Joinder Of Its Petition was served on April 10,
`
`2017 by causing it to be sent by email to counsel for Petitioner Argentum
`
`Pharmaceuticals LLC in IPR2017-01063 and Petitioner Par Pharmaceutical, Inc. in
`
`IPR2016-01479 at the following email addresses:
`
`Argentum Pharmaceuticals LLC
`
`Kevin B. Laurence (klaurence@lpiplaw.com)
`
`Matthew C. Philips (mphilips@lpiplaw.com)
`
`Tyler Liu (tliu@agpharm.com)
`
`Par Pharmaceutical, Inc.
`
`Daniel Brown (daniel.brown@lw.com)
`
`Jonathan M. Strang (jonathan.strang@lw.com)
`
`
`
`Dated: April 10, 2017
`
`
`
`
`
`
`
`
`
`FCHS_WS 13315681v1.doc
`
`
`
`- 3 -
`
`
`
`
`
`/Nicholas N. Kallas/
`Nicholas N. Kallas
`Registration No. 32,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`